Maggie L. Shaw

Maggie L. Shaw

Maggie is a lead editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and Evidence-Based Oncology, for which she produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and she has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.

Articles by Maggie L. Shaw

In the second part of a 2-part preview interview in advance of this year’s virtual 2020 Community Oncology Conference, The American Journal of Managed Care® speaks with Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, about how she is helping employer organizations navigate their pharmacy benefits managers and manage employee expectations.

In the first part of a 2-part preview interview in advance of this year’s virtual 2020 Community Oncology Conference, The American Journal of Managed Care® speaks with Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, about how she is helping employer organizations navigate their pharmacy benefits managers and manage employee expectations.

Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma with a typically poor prognosis. Even with an allogeneic stem cell transplant, patients can become resistant to chemotherapy. Most do not survive 4 or 5 years after diagnosis, and the 10-year survival rate hovers between 5% and 10%.

Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by reducing their levels of low-density lipoprotein cholesterol (LDL-C). These individuals have a risk of cardiovascular disease that is almost twice that of HIV-negative individuals.

Ovarian cancer remains the most deadly of the gynecologic cancers. Researchers from Dana-Farber Cancer Institute may have discovered biomarkers that could predict which patients with platinum-resistant ovarian cancer would benefit from combination poly-ADP ribose polymerase (PARP) inhibitor/immune checkpoint inhibition treatment, as well as those who should pursue a different course of therapy.

The environment surrounding the coronavirus disease 2019 (COVID-19) pandemic seems to change by the minute. The full extent to which HIV-positive individuals can be affected if they contract COVID-19, because they are immunocompromised, is not known. Recently, the CDC issued guidance for this patient population.

Between 2010 and 2017, there were 327,700 new HIV infections in the United States. Of these, HIV-2 infections accounted for less than 0.03% of the total. It is important to differentiate which HIV strain an individual is infected with because HIV-2 is intrinsically resistant to nonnucleoside reverse-transcriptase inhibitors, which are typically used to treat HIV-1 infections.